Impact of community-associated methicillin resistant staphylococcus aureus on HIV-infected patients

Current HIV/AIDS Reports

Volumn 10, Issue 3, 2013, Pages 244-253

  Cole, Joanna ^a   Popovich, Kyle ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Colonization; Human immunodeficiency virus; Illicit drug use; Incarceration; Infection; Infection control; Infection prevention; Methicillin resistant staphylococcus aureus; Staphylococcus aureus; Treatment

Indexed keywords

CEFTAROLINE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ILLICIT DRUG; LINEZOLID; MACROLIDE; NAFCILLIN; OXACILLIN; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; COMMUNITY ASSOCIATED METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG USE; EPIDEMIC; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INNATE IMMUNITY; LOEFFLER PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; OUTCOME ASSESSMENT; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRISON; RECURRENT INFECTION; RHABDOMYOLYSIS; RISK FACTOR; SEXUAL PRACTICE; SOCIAL NETWORK;

HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 84881481569     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0161-0     Document Type: Article

References (89)

1. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436-44. (Pubitemid 40471451)
2. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279(8):593-8. (Pubitemid 28110205)
3. Anon. Methicillin-Resistant Staphylococcus aureus infections in correctional facilities - - Georgia, California, and Texas, 2001-2003.
4. Baillargeon J, Kelley MF, Leach CT, Baillargeon G, Pollock BH. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis. 2004;38(9):e92-5.
5. Kazakova SV, Hageman JC, Matava M, et al. A clone of Methicillin- Resistant Staphylococcus aureus among professional football players. N Engl J Med N Engl J Med. 2005;352(5):468-75. (Pubitemid 40175973)
6. Begier EM, Frenette K, Barrett NL, et al. A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. 2004;39(10):1446-53. (Pubitemid 39518207)
7. Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, CA, in 2002. J Clin Microbiol. 2004;42(9):4050-3. (Pubitemid 39296122)
8. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100-7. (Pubitemid 40053465)
9. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by Community-Associated Methicillin-Resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352(14):1445-53. (Pubitemid 40471452)
10. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis. 2006;42(5):647-56. (Pubitemid 43271378)
11. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis. 2004;39(7):971-9. (Pubitemid 39313452)
12. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-Resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-74.
13. • Popovich KJ, Weinstein RA, Aroutcheva A, Rice T, Hota B. Community-associated methicillin-resistant Staphylococcus aureus and HIV: intersecting epidemics. Clin Infect Dis. 2010;50(7):979-987. This study documented the disproportionate impact CA-MRSA has had on HIV-infected patients in comparison to HIV-negative patients.
14. Shet A, Mathema B, Mediavilla JR, et al. Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. J Infect Dis. 2009;200(1):88-93.
15. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148(4):249-57. (Pubitemid 351665484)
16. Anon. CDC - MRSA and the workplace - NIOSH workplace safety and health topic.
17. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(5):752-60. (Pubitemid 351321562)
18. Popovich KJ, Weinstein RA. Commentary: the graying of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol. 2009;30(1):9-12.
19. Popovich K, Weinstein R, Aroutcheva A, Rice T, Hota B. Community-associated Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSIs) - Evolving Epidemiology? In: San Diego: Society for Healthcare Epidemiology of America; 2009.
20. McDougal LK, Steward CD, Killgore GE, et al. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41(11):5113-20. (Pubitemid 37429924)
21. Diep BA, Sensabaugh GF, Somboonna N, et al. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol. 2004;42(5):2080-4. (Pubitemid 38637826)
22. • Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(1):43-54. In this meta-analysis of the published data on the association of PVL-producing S. aureus and disease manifestations, PVL-producing S. aureus infections were more likely to be associated with SSTIs rather than invasive disease and were not associated with worse outcomes, suggesting that PVL is not the main determinant of disease severity.
23. Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet. 2006;367(9512):731-9. (Pubitemid 43326291)
24. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med. 2007;13(12):1405-6. (Pubitemid 350224232)
25. Crum-Cianflone NF, Burgi AA, Hale BR. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS. 2007;18(8):521-6. (Pubitemid 351738938)
26. Hidron AI, Moanna A, Rimland D. The rise and fall of methicillin- resistant Staphylococcus aureus infections in HIV patients. AIDS. 2011;25(7):1001-3.
27. Furuno JP, Johnson JK, Schweizer ML, et al. Community-associated methicillin-resistant Staphylococcus aureus bacteremia and endocarditis among HIV patients: a cohort study. BMC Infect Dis. 2011;11:298.
28. Ramsetty SK, Stuart LL, Blake RT, Parsons CH, Salgado CD. Risks for methicillin-resistant Staphylococcus aureus colonization or infection among patients with HIV infection. HIV Med. 2010;11(6):389-94.
29. Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr. 2005;40(2):155-60. (Pubitemid 41395713)
30. Graber CJ, Jacobson MA, Perdreau-Remington F, Chambers HF, Diep BA. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic. J Acquir Immune Defic Syndr. 2008;49(2):231-3.
31. Crum-Cianflone N, Weekes J, Bavaro M. Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors. AIDS Patient Care STDS. 2009;23(7):499-502.
32. Skiest D, Brown K, Hester J, et al. Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic. HIV Med. 2006;7(6):361-8. (Pubitemid 44123246)
33. Szumowski JD, Wener KM, Gold HS, et al. Methicillin-resistant Staphylococcus aureus colonization, behavioral risk factors, and skin and soft-tissue infection at an ambulatory clinic serving a large population of HIV-infected men who have sex with men. Clin Infect Dis. 2009;49(1):118-21.
34. Shastry L, Rahimian J, Lascher S. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections in men who have sex with men in New York City. Arch Intern Med. 2007;167(8):854-7. (Pubitemid 46658347)
35. Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997;10(3):505-20. (Pubitemid 27359263)
36. • Yang ES, Tan J, Eells S, et al. Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect. 2010;16(5):425-431. This study of S. aureus colonization at different anatomic sites in patients with an acute SSTI is one of the first reports to suggest that CA-MRSA may have distinct colonization patterns. In patients with acute S. aureus SSTIs, extra-nasal colonization with CA-MRSA was more common than patients with MSSA infections or HA-MRSA infections.
37. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis. 2008;197(9):1226-34. (Pubitemid 351632753)
38. •• Popovich KJ, Smith KY, Khawcharoenporn T, et al. Community-associated methicillin-resistant Staphylococcus aureus colonization in high-risk groups of HIV-infected patients. Clin Infect Dis. 2012;54(9):1296-1303. Outpatient study demonstrating higher prevalence of CA-MRSA nares colonization in HIV-infected patients compared to HIV-negative. Within HIV-infected patients there is variation in prevalence of CA-MRSA colonization, with women and individuals who were recently incarcerated having the highest prevalence.
39. Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr. 2008;48(5):567-71.
40. Peters PJ, Brooks JT, Limbago B, et al. Methicillin-resistant Staphylococcus aureus colonization in HIV-infected outpatients is common and detection is enhanced by groin culture. Epidemiol Infect. 2010:1-11.
41. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344(1):11-6. (Pubitemid 32064839)
42. Hota B, Ellenbogen C, Hayden MK, et al. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections at a public hospital: do public housing and incarceration amplify transmission? Arch Intern Med. 2007;167(10):1026-33. (Pubitemid 46835790)
43. • Popovich KJ, Hota B, Aroutcheva A, et al. Community-associated methicillin-resistant staphylococcus aureus colonization burden in HIV-infected patients. Clin Infect Dis. 2013 Apr;56(8):1067-74. Prospective evaluation for CA-MRSA colonization at multiple anatomic sites at time of admission for HIV-infected and HIV-negative patients found that HIV-infected patients are more likely to have extra-nasal colonization with CA-MRSA, with 38 % of colonized patients having exclusive extra-nasal colonization with MRSA.
44. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis. 2005;40(10):1529-34. (Pubitemid 40628644)
45. Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun. 2010;78(1):32-8.
46. Fischer-Stabauer M, Boehner A, Eyerich S, et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol. 2012;22(6):781-4.
47. El Hed A, Khaitan A, Kozhaya L, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis. 2010;201(6):843-54.
48. Burkey MD, Wilson LE, Moore RD, et al. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era. HIV Med. 2008;9(10):858-62.
49. Cook HA, Furuya EY, Larson E, Vasquez G, Lowy FD. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44(3):410-3. (Pubitemid 46151062)
50. Anon. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison - Mississippi, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(42):919-22.
51. David MZ, Mennella C, Mansour M, Boyle-Vavra S, Daum RS. Predominance of methicillin-resistant Staphylococcus aureus among pathogens causing skin and soft tissue infections in a large urban jail: risk factors and recurrence rates. J Clin Microbiol. 2008;46(10):3222-7.
52. Lowy FD, Aiello AE, Bhat M, et al. Staphylococcus aureus colonization and infection in New York State prisons. J Infect Dis. 2007;196(6):911-8. (Pubitemid 47378942)
53. Anon. Health status of soon-to-be-released inmates.
54. Spaulding AC, Seals RM, Page MJ, et al. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558.
55. Hartley DM, Furuno JP, Wright MO, Smith DL, Perencevich EN. The role of institutional epidemiologic weight in guiding infection surveillance and control in community and hospital populations. Infect Control Hosp Epidemiol. 2006;27(2):170-4. (Pubitemid 43384763)
56. Farley JE, Ross T, Stamper P, et al. Prevalence, risk factors, and molecular epidemiology of methicillin-resistant Staphylococcus aureus among newly arrested men in Baltimore, Maryland. Am J Infect Control. 2008;36(9):644-50.
57. Popovich K, Hota B, Rice T, Aroutcheva A, Weinstein RA. Phenotypic prediction rule for community-associated methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2007;45(7):2293-5. (Pubitemid 47203812)
58. McDougal LK, Fosheim GE, Nicholson A, et al. Emergence of resistance among USA300 Methicillin-Resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother. 2010;54(9):3804-11.
59. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol. 2007;45(4):1350-2. (Pubitemid 46626515)
60. •• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55. Recently published guidelines for treatment of MRSA based on graded evidence and expert opinion.
61. Hammond SP, Baden LR. Management of skin and soft-tissue infection - polling results. N Engl J Med. 2008;359(15):e20. doi: 10.1056/NEJMclde0806337.
62. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2007;51(11):4044-8. (Pubitemid 350057804)
63. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23(2):123-7. (Pubitemid 38222783)
64. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777-84. (Pubitemid 46365300)
65. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(7):2628-30. (Pubitemid 47047353)
66. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991;163(6):1279-85.
67. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55(4):582-6.
68. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398-402. (Pubitemid 38747480)
69. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340-7.
70. Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.
71. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for Bacteremia and Endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-65.
72. Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006;42(12):e108-10.
73. Kim PW, Sorbello AF, Wassel RT, et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447-57.
74. Silverman JA, Mortin LI, Vanpraagh ADG, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191(12):2149-52. (Pubitemid 40800587)
75. File Jr TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55 Suppl 3:S173-80.
76. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis 2nd JS. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267-70.
77. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346(24):1871-7. (Pubitemid 34605989)
78. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178-85. (Pubitemid 46079977)
79. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin- resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother. 2007;51(10):3591-8. (Pubitemid 47519348)
80. Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis. 1999;180(3):896-9. (Pubitemid 29411387)
81. Gordon RJ, Chez N, Jia H, et al. The NOSE study (nasal ointment for Staphylococcus aureus eradication): a randomized controlled trial of monthly mupirocin in HIV-infected individuals. J Acquir Immune Defic Syndr. 2010;55(4):466-72.
82. Vasquez JE, Walker ES, Franzus BW, et al. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol. 2000;21(7):459-64. (Pubitemid 30620214)
83. McGann P, Yoon I, Kwak MS, Summers A, et al. Detection of qacA/B in clinical isolates of Methicillin-Resistant Staphylococcus aureus from a regional healthcare network in the Eastern United States. Infect Control Hosp Epidemiol. 2011;32(11):1116-9.
84. • Daum RS, Spellberg B. Progress toward a staphylococcus aureus vaccine. Clin Infect Dis. 2011 Feb 15;54(4):560-7. Review of the efforts in S. aureus vaccine development to date and the specific pathogen and disease specific challenges involved in successful vaccine development.
85. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med. 2002;346(7):491-6. (Pubitemid 34441740)
86. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine. 2012;30(19):2921-7.
87. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009;5(12):e1000703.
88. Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005;40(10):1429-34. (Pubitemid 40628630)
89. Bowen AC, Lilliebridge RA, Tong SYC, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol. 2012;50(12):4067-72.